Nipro newsletter April 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Current Features

Advertisement

Current Edition

Current Edition demo 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do...

Advertisement

DDL 2026

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Advertisement

Nipro April 2026
Current Features

Evolving Quality Risk Management: A Deep Dive into ICH Q9 (R1) with Kevin O’Donnell (HPRA) on the Pharma Conversations Podcast

In a recent episode of the Pharma Conversations podcast, Kevin O’Donnell of the Health Products Regulatory Authority (HPRA) offered a detailed and thought-provoking ...
Continue Reading →
Current Features

Solstice Advanced Materials on Powering the Global Shift to Low-GWP Inhaler Propellants

Solstice Advanced Materials outlines its perspective on the transition to lowGWP propellants in an interview with International Pharmaceutical Industry Journal, ...
Continue Reading →
Current Features

Terumo Pharmaceutical Solutions on Integrated CDMO Services

International Pharmaceutical Industry Journal speaks with Michele Guasti, Global Product Manager at Terumo Pharmaceutical Solutions Division. The discussion explores...
Continue Reading →
Current Features

PFAS and Pharmaceuticals: Why the Industry Can No Longer Afford to Wait

Few regulatory issues have the potential to reshape pharmaceutical manufacturing as profoundly as PFAS. Often referred to as "forever chemicals", per- and polyfluoro...
Continue Reading →
Current Features

Differences Between US and EU Pre- and Post-Market Regulatory Obligations

Typically, global companies developing innovative therapies are familiar with the differences between regulatory systems in the United States and European Union. In ...
Continue Reading →
Current Features

Why Predictive Analytics are Crucial for Effective EU-HTAR Implementation

The EU’s Health Technology Assessment Regulation (EU-HTAR) aims to introduce more harmonised, efficient and evidencebased assessments of new health technologies. How...
Continue Reading →

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak – 21.05.2025

Advertisement

Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025

Company Profiles